CompletedPhase 1NCT01997632

Phase 1 Study on the Safety and Reactogenicity of a Single Dose of Monovalent High-dose Inactivated Poliovirus Type 2 Vaccine (m-IPV2 HD) Given Intramuscularly Compared to Standard Trivalent Inactivated Poliovirus Vaccine (IPV) in Healthy Adults

Studying Poliomyelitis

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University Hospital, Ghent
Principal Investigator
Geert Leroux-Roels, MD, PhD
University Hospital, Ghent
Intervention
a single dose of monovalent high-dose inactivated poliovirus type 2 vaccine (m-IPV2 HD)(biological)
Enrollment
120 target
Eligibility
18-45 years · All sexes
Timeline
2013 – 2014

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01997632 on ClinicalTrials.gov

Other trials for Poliomyelitis

Additional recruiting or active studies for the same condition.

See all trials for Poliomyelitis →

← Back to all trials